Our top pick for
Morphic Holding, Inc is a biotechnology business based in the US. Morphic Holding shares (MORF) are listed on the NASDAQ and all prices are listed in US Dollars. Morphic Holding employs 87 staff and has a trailing 12-month revenue of around USD$38.7 million.
|52-week range||USD$9.9 - USD$41|
|50-day moving average||USD$33.7415|
|200-day moving average||USD$29.8662|
|Wall St. target price||USD$45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-17.629|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Morphic Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Morphic Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Morphic Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Morphic Holding shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$38.7 million|
|Gross profit TTM||USD$-36,755,000|
|Return on assets TTM||-12.92%|
|Return on equity TTM||-32.51%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 1.8 million Morphic Holding shares held short by investors – that's known as Morphic Holding's "short interest". This figure is 29.2% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Morphic Holding shares can be evaluated.
Morphic Holding's "short interest ratio" (SIR) is the quantity of Morphic Holding shares currently shorted divided by the average quantity of Morphic Holding shares traded daily (recently around 155404.71698113). Morphic Holding's SIR currently stands at 11.66. In other words for every 100,000 Morphic Holding shares traded daily on the market, roughly 11660 shares are currently held short.
However Morphic Holding's short interest can also be evaluated against the total number of Morphic Holding shares, or, against the total number of tradable Morphic Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Morphic Holding's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Morphic Holding shares in existence, roughly 60 shares are currently held short) or 0.1484% of the tradable shares (for every 100,000 tradable Morphic Holding shares, roughly 148 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Morphic Holding.
Find out more about how you can short Morphic Holding stock.
We're not expecting Morphic Holding to pay a dividend over the next 12 months.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR ß6 #2, a selective avß6 specific integrin inhibitor to treat IPF and PSC; and avß1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics; and drug discovery research collaboration with HitGen Inc. to identify small molecule leads against targets specified by the company. The company was founded in 2014 and is based in Waltham, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.